Product Information
MONTELUKAST SOD 4 MG GRANULES is a generic product labeled by Aurobindo Pharma Limited, priced at $0.8126 per EA under NDC 59651032930. Its NADAC has been published 314 times since Sep 30, 2020.
FDA first approved this application on Feb 18, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Aurobindo Pharma LimitedNDC
59651032930
Classification
Generic
Dosage Form
GRANULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MONTELUKAST SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA213471FDA Approved
2/18/2020
TE Code
AB
On Market Since
2/18/2020
Pharmacological Classes
Price Statistics
The NADAC for MONTELUKAST SOD 4 MG GRANULES has been published 314 times since Sep 30, 2020, and over the history we have for it it has declined 48.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8126 per EA |
|---|---|
| All-time high | $1.6003 (May 11, 2022) |
| All-time low | $0.8061 (May 22, 2024) |
| 52-week high | $1.1226 |
| 52-week low | $0.8126 |
| Median price | $1.1187 |
| Average price | $1.1618 |
| Largest weekly change | +39.7% (Mar 20, 2024) |
| Weeks tracked | 314 |
| Tracking since | Sep 30, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Montelukast Sodium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurobindo Pharma Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Montelukast Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Leukotriene Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MONTELUKAST SOD 4 MG GRANULES?
The current National Average Drug Acquisition Cost (NADAC) for MONTELUKAST SOD 4 MG GRANULES, manufactured by Aurobindo Pharma Limited, is $0.8126 per EA (NDC 59651032930), effective Sep 30, 2026.
How has the price of MONTELUKAST SOD 4 MG GRANULES changed over time?
Over the history we have for it, the NADAC for MONTELUKAST SOD 4 MG GRANULES has declined 48.6%. It has been tracked across 314 weekly CMS publications since Sep 30, 2020.
What are the highest and lowest recorded NADAC prices for MONTELUKAST SOD 4 MG GRANULES?
Since Sep 30, 2020, the NADAC for MONTELUKAST SOD 4 MG GRANULES has ranged from a low of $0.8061 (May 22, 2024) to a high of $1.6003 (May 11, 2022), with a median of $1.1187 per EA.
Are there cheaper alternatives to MONTELUKAST SOD 4 MG GRANULES?
No other NADAC-published product currently shares the active ingredient and strength of MONTELUKAST SOD 4 MG GRANULES in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures MONTELUKAST SOD 4 MG GRANULES?
MONTELUKAST SOD 4 MG GRANULES (NDC 59651032930) is labeled by Aurobindo Pharma Limited, and CMS classifies it as a generic product.